Experimental drug inavolisib targets Hard-to-Treat pancreatic cancer
NCT ID NCT07694973
First seen Jul 10, 2026 · Last updated Jul 10, 2026
Summary
This phase 2 trial tests the drug inavolisib in people with pancreatic ductal adenocarcinoma whose cancer has worsened after prior chemotherapy. The study aims to see if inavolisib can shrink tumors or slow disease progression. Participants take inavolisib daily by mouth, and their tumors are scanned every 8 weeks. The trial also collects tumor and blood samples to study biomarkers that may predict response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- inavolisib
- What this could lead to
- If successful, this could provide a new treatment option for patients with pancreatic cancer that has progressed after initial therapy.
- What could go wrong
- This is an early phase 2 trial with a small number of participants, so results may not confirm benefit. Side effects may limit tolerability.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, China
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Breath of life: new test could sniff out gut cancers before they spread
- Scientists hunt for biomarkers to catch pancreatic cancer before it strikes
- New PET tracer aims to spot hidden cancer spread in the abdomen
- Mini-Tumors in a dish may guide pancreatic cancer treatment
- New drug cocktail aims to tackle tough pancreatic cancer
- New pill targets Hard-to-Treat cancers with a specific gene mutation